Fact CheckerSign in

NCT06926400Not yet recruiting

The Effectiveness and Safety of the Coronary Artery Serrated Cutting Balloon Dilation Catheter in the Pre-dilation of Coronary Artery Stenosis Lesions

A Prospective, Multicenter, Randomized Controlled Clinical Trial to Evaluate the Effectiveness and Safety of the Coronary Artery Serrated Cutting Balloon Dilation Catheter for the Predilation of Coronary Artery Stenosis Lesions

Source: ClinicalTrials.gov · Last updated 13 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

To evaluate the effectiveness and safety of the coronary serrated cutting balloon dilation catheter for the pre-dilation of coronary artery stenosis lesions.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
182 (estimated)
First submitted
1 Apr 2025
Start date
10 Apr 2025
Primary completion date
30 Dec 2025
Lead sponsor
JW Medical Systems Ltd
NCT number
NCT06926400

What you commit to

  • Study type: Interventional
  • Planned participants: 182
  • From 10 Apr 2025 to the primary completion date, 30 Dec 2025
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Lab values

  • General Exclusion Criteria
    • Patients with New York Heart Association (NYHA) Class IV heart failure.
    • Patients with contraindications to anti - platelet and anticoagulant therapy and are unable to receive anticoagulant treatment.
    • Patients who have had any myocardial infarction within one week.
    • Patients with an allergic reaction to contrast agents. ⑤ Patients with severe renal failure, with a serum creatinine level \> 2.0 mg/dl (177 μmol/L).
    • Patients who have undergone heart transplantation.
    • Patients who have had active peptic ulcer or active gastrointestinal bleeding within 1 month before surgery.
    • ⑧ Patients who have had a stroke or transient ischemic attack within 3 months before surgery.
    • Pregnant or lactating patients. ⑩ Patients who are currently participating in any other clinical trials. ⑪ Patients whom the investigator deems unsuitable for enrollment. Exclusion Criteria Related to the Target Lesion (Detected by Coronary Angiography)
    • Tortuous lesions or lesions with an angulation of ≥ 45 degrees at the lesion site.
    • Lesions at the ostium with a distance of ≤ 2 mm from the left main coronary artery.
    • Unprotected left main coronary artery lesions. ④ Coronary angiography shows the presence of thrombus. ⑤ Before using the test device or the control device, the target lesion has a dissection of Type C or higher.
    • Target lesions that require treatment with coronary atherectomy or special balloons (such as scored balloons, spiked balloons, shock - wave lithotripsy systems, and cutting balloons of other brands).

Who the study is looking for

  • ① The age is between 18 and 80 years old (including the boundary values), and the subjects are male or non-pregnant female.
    • Have single or multiple coronary artery lesions and diagnosed ischemic heart disease (for example: stable angina pectoris, unstable angina pectoris, old myocardial infarction or asymptomatic myocardial ischemia).
    • There are coronary artery stenosis lesions confirmed by coronary angiography, which are suitable for percutaneous coronary intervention. The coronary artery stenosis is ≥ 70% (by visual estimation); or ≥ 50% (by visual estimation) and accompanied by evidence of ischemia, and the TIMI blood flow is ≥ Grade 1.
    • There are de novo or restenosis lesions in the coronary arteries of autologous or bypass graft vessels, and interventional treatment is required.
    • The visually estimated reference vessel diameter of the target lesion is 2.0mm - 4.0mm, and the lesion length is ≤ 20mm.
    • When there are multiple lesions that need to be treated, only one coronary artery lesion is selected as the target lesion, and the non-target lesions must be located on different vascular branches.
    • Be able to understand the purpose of the study, voluntarily participate and sign the informed consent form, and be able to and willing to accept the follow-up as specified in this trial.

Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.